Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.
about
Barriers to a cure for HIV in womenClinical effectiveness of dolutegravir in the treatment of HIV/AIDSDolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVResistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistencePreventing HIV infection: pre-exposure and postexposure prophylaxisPharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women.The role of dolutegravir in the management of HIV infectionPharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaquesPharmacokinetics of antiretrovirals in mucosal tissueDose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults.Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.Abacavir + dolutegravir + lamivudine for the treatment of HIV.Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers.Ultra-long-acting removable drug delivery system for HIV treatment and prevention
P2860
Q26768632-0DA7AF20-466F-4987-B042-2ACBB438D395Q26778450-FC851FA2-A76F-4E93-B59D-11838CCB0897Q26799712-5465C83C-0C48-4518-963C-655AE27CB4F8Q26801286-F4E03772-4055-40D0-A682-4EAE4117837CQ26828445-3CBE2B4B-BCA4-4E59-9889-6A042D806781Q33888718-62CE85BA-DC19-4745-A298-129221605CD1Q35102123-2DBB225E-6E43-4CFC-9A4A-AFBCA241CECCQ35121450-4DEA43C3-7578-4A91-8BB3-897D6370D9A9Q35432739-0A636643-3FE9-4277-B8A9-54305A5B5C26Q35838594-88D5E087-DAAD-46DD-BB05-3954E0A052BFQ36406923-EC71430E-2091-4C8D-8971-92EFB489DD77Q37592039-D6583F78-37EA-4AE2-A93A-1B20BD34064AQ38227491-F8B76BDD-6504-47C0-A90E-C57DAEEE46D2Q38362394-830F6C9A-C391-4C6E-B7D7-323633ABE84FQ38951349-FBB6981C-86DB-480A-9A1D-C015B4BFC998Q47800916-94E06386-C534-4C7B-9736-6AED81FC9061Q57295387-6B7E9264-2FC6-42D9-87BC-E7167F06CFC1
P2860
Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Single and multiple dose pharm ...... l tract of HIV-negative women.
@ast
Single and multiple dose pharm ...... l tract of HIV-negative women.
@en
type
label
Single and multiple dose pharm ...... l tract of HIV-negative women.
@ast
Single and multiple dose pharm ...... l tract of HIV-negative women.
@en
prefLabel
Single and multiple dose pharm ...... l tract of HIV-negative women.
@ast
Single and multiple dose pharm ...... l tract of HIV-negative women.
@en
P2093
P2860
P356
P1433
P1476
Single and multiple dose pharm ...... l tract of HIV-negative women.
@en
P2093
Angela D M Kashuba
Benjamin N Greener
Craig Sykes
Heather M A Prince
Jessica L Adams
Julie B Dumond
Kristine B Patterson
P2860
P304
P356
10.3851/IMP2665
P577
2013-07-31T00:00:00Z